Loading...
AC Immune SA (ACIU) is not a good buy for a beginner investor with a long-term focus at this time. The company's financial performance is significantly deteriorating, with revenue, net income, and EPS showing sharp declines. Additionally, there are no strong technical or trading signals to suggest a promising entry point. While the options data indicates a low put-call ratio, suggesting minimal bearish sentiment, the lack of positive catalysts and the absence of recent news or analyst upgrades make this stock unsuitable for investment at the moment.
The MACD is below zero and negatively contracting, indicating bearish momentum. RSI is neutral at 63.453, showing no clear signal. Moving averages are converging, and the stock is trading near its resistance level (R1: 2.972). Overall, the technical indicators do not suggest a strong buy signal.

NULL identified. No recent news, analyst upgrades, or significant trading trends.
The company's financial performance is severely declining, with revenue down 96.32% YoY, net income down 388.17% YoY, and EPS down 420.00% YoY. No recent insider or hedge fund activity, and no significant trading trends.
In Q3 2025, revenue dropped by 96.32% YoY to $939,000. Net income fell by 388.17% YoY to -$15,858,000. EPS declined by 420.00% YoY to -$0.16. Gross margin remained at 100%, unchanged YoY.
No data available for recent analyst ratings or price target changes.